BioNTech R&D Austria, a wholly owned subsidiary of BioNTech SE since October 2021, is a research hub within the BioNTech Group specializing in the development of new anti-bacterial agents. At the site in Vienna, Austria, a team of approximately 20 scientists research and develop precision therapies against bacterial infections.
ViruSure is a privately owned biotech company specialising in the virus and prion safety testing of biopharmaceutical products. We offer contract testing services and a wealth and breadth of expertise to ensure you meet all relevant pathogen safety testing requirements. Our goal is to ensure that the strategy we develop with you will provide a high chance of success in satisfying all regulatory requirements at the first attempt.
Akribes Biomedical is dedicated to the improvement of chronic wound therapy. We developed the first theranostic assay platform to enable personalized pharmacological therapy of chronic wounds. Based on this platform we identified and patented drugs with so far unknown potential for chronic wound healing, which will be developed as novel wound therapeutics.
Our mission is to make a novel therapeutic approach a reality in Peritoneal Dialysis (PD) – an area where clinicians and patients saw disappointingly little innovation in decades. Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial.
APEPTICO Forschung und Entwicklung GmbH is a privately-held development stage biotechnology company in Vienna, Austria, developing peptide-based products targeting life-threatening pulmonary diseases.
Pivaris BioScience GmbH is a privately held Research
THT Biomaterials GmbH aims to overcome major methodological issues at the bottom of today’s drug development, tissue engineering and regenerative medicine research practices leading to false positive or negative results. A new visionary platform technology is under development that will speed up research as it makes its results more realistic by replacing animal components with human components (https://tht-biomaterials.com).
HeartBeat.bio is an early-stage drug discovery company focused on the development of a high-throughput fully human 3D screening platform for heart diseases. The technology has the potential to radically change the current cardiovascular drug discovery paradigm, leading to higher success rates in clinical trials, reduced cost and time for compound development. HeartBeat.bio’s business strategy is to leverage its screening technology into multiple R
SAICO is a Vienna-based company founded in 2017 that focuses on the microfabrication of biosensors and lab-on-a-chip systems for biomedical applications. We facilitate the rapid translation of academic innovations into industrial production of diagnostic tools for personalized medicine. Our core competence is the rapid and cost-efficient generation of functional prototypes needed to reduce the development time from initial idea to market-ready devices.
Ablevia develops a new class of infusible therapeutics to selectively remove harmful and disease-causing antibodies. These therapeutics can be readily adapted to target unwanted antibodies in rare diseases or in conditions with unmet clinical needs. Founded in 2018 at the Vienna Biocenter Campus, Ablevia focuses on IP generation and preclinical research and development.
bit.bio discovery combines single cell functional genomics with best-in-class cellular models to decipher complex cellular pathways and gain a better understanding of disease development. This next-generation CRISPR screening platform will help to understand the role of gene networks at unprecedented scale and resolution to discover and validate novel drug targets.
Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens.
Aposcience AG is unique in having developed a secretome-based regenerative therapy. The secretome is produced under GMP-conditions and was approved by the Austrian regulatory agency for a clinical phase II trial. Our product platform Aposec consists of two products: APO-1 - Aposec for internal diseases (acute myocardial infarction, spinal cord injury and stroke) APO-2 - Aposec for topical application (hard-healing wounds, diabetic ulcers)
YASARA Biosciences develops and distributes the YASARA molecular modelling and simulation program. This acronym stands for Yet Another Scientific Artificial Reality Application, and delineates the software's main purpose: to create an artificial reality inside the computer, atom by atom, visualize it in 3D and let the user interact with it. The focus has always been on biomolecular modelling, covering the most prominent topics (including structure prediction and docking).
Acticell is a research company that develops innovative solutions for new trends in the textile industry. The research and technology start-up has specialized in the field of cellulose chemistry, especially in the textile industry. Acticell know-how can replace life-threatening sandblasting and the environmentally harmful potassium permanganate in bleaching jeans. Worldwide leading jeans labels already rely on production processes with Acticell technology.
Ares Genetics is a sequencing service provider and bioinformatics developer revolutionizing how we address the global challenge of antimicrobial resistance (AMR). Ares Genetics enables better infection control and more targeted patient care by providing unprecedented insight into pathogens and AMR through next generation sequencing (NGS) and artificial intelligence (AI) powered solutions.
NBS-C BioScience is a Contract Research Laboratory founded 2009 as a spin off by leading scientists of the Novartis Institutes for BioMedical Research in Vienna, Austria. In a second business field NBS-C BioScience develops and commercializes research tools and kit components for allergy research and diagnostics.
usePAT offers add-on devices for the improvement of in-line measurements in PAT (Process Analytical Technology) systems. They are compatible with a variety of sensors and can be designed and adapted to the specific needs and requirements of many fields of application. In order to facilitate the process of real-time measuring, our technology takes advantage of well-controlled ultrasonic fields for spatial particle manipulation in liquids.
Pregenerate GmbH is a Vienna- based medtech startup established in November, 2019 with an aim to improve treatment outcomes for osteoarthritis patients by in vitro monitoring of cellular responses to different therapeutics. The Pregenerate team consists of five full time employees with extensive academic and clinical experience, as well as years of expertise in the pharmaceutical industry.